A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
Completed · Phase 3 · NCT02993731
Conditions: Carcinoma, Pancreatic Ductal
At a glance
- Research payments reported, 2025
- $15,000
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 1,134
About the trial
- Sponsor
- Sumitomo Pharma America, Inc.
- Tested
- Napabucasin (drug), Nab-paclitaxel (drug), Gemcitabine (drug)
- Dates
- Started 2016-12; completion 2020-03
- Results posted
- Yes
This is a randomized, open-label, multi-center, phase 3 study of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine for adult patients with Metastatic Pancreatic Ductal Adenocarcinoma.
From ClinicalTrials.gov, last updated 2023-11-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sumitomo Pharma America, Inc. reported $15,000 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Weill Medical College of Cornell University $15,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.